Compare ResMed Inc. (RMD) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Wynn Resorts, Limited — how do they compare? ResMed Inc. trades at $197.45 (market cap $28.81B), while Wynn Resorts, Limited trades at $94.75 (market cap $9.93B). The key difference: ResMed Inc. is far larger — about 2.9× Wynn Resorts, Limited's market cap, and ResMed Inc. pays the higher dividend (1.21%). Which is the better fit depends on your goals.
| RMD | WYNN | |
|---|---|---|
Market Cap | $28.81B | $9.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $293.73 | $133.34 |
52-Week Low | $182.82 | $94.78 |
Enterprise Value | $27.99B | $20.29B |
Dividend Yield | 1.21% | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
Wynn Resorts (WYNN) trades at $94.63, down 2.08% today, amid a bearish technical signal with recent earnings misses. The company maintains strong revenue growth with $7.14B in 2025, though net margins have compressed to 4.58%. Recent news highlights operational awards and Q2 2026 earnings anticipation. Technical indicators show support near $93-$95 with resistance at $97-$99, while RSI levels suggest neutral momentum.
Outlook remains mixed: analyst consensus is bullish with a $135.50 price target (64% buy ratings), but high debt ($10.5B long-term) and margin pressure pose risks. The stock offers potential upside if Macau and Las Vegas momentum sustains, though geopolitical and competitive headwinds require monitoring. Near-term catalysts include Q2 earnings on August 4, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
